14
May
Indian pharma major Cipla is looking at a high-risk recovery plan for FY27, after a tough fourth quarter, that saw its consolidated net profit plummet 54.6% to ₹5.55 billion. The decline in earnings was primarily driven by a 26% year-on-year decline in North America revenues to ₹14.14 billion, as the company faced intense generic competition and a lack of high-margin assets. Performance was further hit by a ₹420 million impairment charge and a suspension of sales of key cancer drug Lanreotide due to regulatory issues at a partner facility. These setbacks notwithstanding, the company continued to see the domestic market…
